Foundayo (Orforglipron) vs the Injectables: What the New GLP-1 Pill Actually Buys You
The first GLP-1 pill with no needle and no food rule just got approved. It loses real weight, but trails the strongest shot by about 8 points.
FEATURED DOSSIER
Before you buy a test booster or book a TRT clinic, get bloodwork. What the natural levers actually do, where a booster fits, and when TRT is a real decision.
Most men deciding this are deciding in the wrong order. Symptoms get blamed on low testosterone, and the shopping starts. The sharper sequence is cheap and dull: test first, fix the basics, then consider a modest supplement, and only then talk to a clinician about therapy.
Practical decision files for men over 40 who want the readout before they spend. New to Sterling? Start with the Men's Health After 40 field guide.
The first GLP-1 pill with no needle and no food rule just got approved. It loses real weight, but trails the strongest shot by about 8 points.
The new Oura Ring 5 is here, but the device that was independently tested is the cheaper Ring 4, and the new GLP-1 and metabolic features are not Ring 5 only.
Ashwagandha lowers cortisol in real trials, but only one extract has the evidence, and the calm can tip into emotional flatness.
Methylene blue is being sold as a cognitive enhancer and mitochondrial booster for men over 40.
The evidence on creatine monohydrate is among the strongest in sports nutrition.
Kyzatrex and Jatenzo are FDA-approved oral testosterone options that skip the needle. They work.
Who We Are
Sterling Confidential is a private-intelligence desk for men over 40. The problem is rarely a shortage of advice; it is the flood of it. Every supplement, wearable, and protocol is sold as the answer. We publish dossiers that cut through the noise: each one names the decision you are actually facing, what the evidence says, what to measure first, and what would make the purchase unnecessary.
We sell clarity, not transformation. Every health claim is traced to a cited source, every verdict is bounded by the weakest evidence behind it, and we say plainly who should skip. We may earn from affiliate links, but compensation never buys a recommendation. The goal is simple: you leave sharper, even if you buy nothing.
Our Editorial Policy